Rigel Pharmaceuticals, Inc. (RIGL)

NASDAQ: RIGL · IEX Real-Time Price · USD
1.470
-0.080 (-5.16%)
At close: Mar 4, 2024, 4:00 PM
1.450
-0.020 (-1.36%)
After-hours: Mar 4, 2024, 7:30 PM EST
-5.16%
Market Cap 270.27M
Revenue (ttm) 132.37M
Net Income (ttm) -24.43M
Shares Out 174.37M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,537,171
Open 1.560
Previous Close 1.550
Day's Range 1.455 - 1.560
52-Week Range 0.710 - 1.960
Beta 0.96
Analysts Strong Buy
Price Target 6.67 (+353.74%)
Earnings Date Mar 5, 2024

About RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (I... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 29, 2000
Employees 155
Stock Exchange NASDAQ
Ticker Symbol RIGL
Full Company Profile

Financial Performance

In 2022, RIGL's revenue was $120.24 million, a decrease of -19.43% compared to the previous year's $149.24 million. Losses were -$58.57 million, 227.0% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for RIGL stock is "Strong Buy." The 12-month stock price forecast is $6.67, which is an increase of 353.74% from the latest price.

Price Target
$6.67
(353.74% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , Feb. 27, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2023 financial results after...

6 days ago - PRNewsWire

Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®

GAVRETO® (pralsetinib) is an FDA approved targeted therapy for the treatment of RET fusion-positive metastatic non-small cell lung cancer and advanced or metastatic thyroid cancer Acquisition of estab...

11 days ago - PRNewsWire

Rigel Pharmaceuticals Provides Business Update

Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE® net product sales of $25.7 million and REZLIDHIA® net product sales of $3.9 million Strate...

2 months ago - PRNewsWire

Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Jan. 5, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to Rigel's Inducement Plan, approved...

2 months ago - PRNewsWire

Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

SOUTH SAN FRANCISCO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced a collaboration with CONNECT, an international collaborative network of pediatric ...

2 months ago - PRNewsWire

Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Jan. 3, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company overv...

2 months ago - PRNewsWire

Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers

SOUTH SAN FRANCISCO, Calif. and HOUSTON , Dec. 8, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a ...

3 months ago - PRNewsWire

Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update

Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE® net product sales of $24.5 million and REZLIDHIA® net product sales of $2.7 million New data on olutasidenib in mIDH1...

4 months ago - PRNewsWire

Rigel to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company o...

4 months ago - PRNewsWire

Rigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition

-- Growing body of data on REZLIDHIA® (olutasidenib) in mIDH1 relapsed or refractory (R/R) acute myeloid leukemia (AML) patients -- -- New data on olutasidenib in patients with mIDH1 myelodysplastic s...

4 months ago - PRNewsWire

Rigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , Oct. 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2023 financial results after market close o...

4 months ago - PRNewsWire

Rigel Announces Presentation at the Upcoming IDWeek 2023

-- Provides Update on ACTIV-4 Host Tissue Trial -- SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming oral presentation ...

5 months ago - PRNewsWire

Rigel to Present at the 2023 Cantor Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Sept. 20, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company...

5 months ago - PRNewsWire

Rigel to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dea...

6 months ago - PRNewsWire

Rigel Reports Second Quarter 2023 Financial Results and Provides Business Update

Second quarter 2023 Total Revenue of $26.9 million which includes TAVALISSE® net product sales of $21.3 million and REZLIDHIA® net product sales of $2.6 million Development programs continue to advanc...

7 months ago - PRNewsWire

Rigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , July 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2023 financial results after market close ...

7 months ago - PRNewsWire

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , July 5, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. I...

8 months ago - PRNewsWire

Rigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML

Durable remissions observed in patients relapsed or refractory to prior venetoclax-based regimens Data featured in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congre...

9 months ago - PRNewsWire

Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances

Review article examines the preclinical and clinical development, and the role of olutasidenib in the mIDH1 AML treatment landscape. Authors conclude, "The approval of olutasidenib is a critical addit...

9 months ago - PRNewsWire

Rigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting

SOUTH SAN FRANCISCO, Calif. , June 1, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced an upcoming poster presentation highlighting the Company's IRAK1/4 program at the ...

9 months ago - PRNewsWire

Rigel to Present at the Jefferies 2023 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , May 31, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will pre...

9 months ago - PRNewsWire

Rigel Reports First Quarter 2023 Financial Results and Provides Business Update

First quarter 2023 Total Revenue of $26.1 million which includes TAVALISSE® net product sales of $22.3 million and REZLIDHIA® net product sales of $1.5 million Global expansion of TAVALISSE in ITP wit...

10 months ago - PRNewsWire

Rigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , April 25, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2023 financial results after market close ...

11 months ago - PRNewsWire

Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE® net product sales of $21.9 million and REZLIDHIA™ net product sales of $0.9 million REZLIDHIA U.S. commercial launch contin...

1 year ago - PRNewsWire

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , Feb. 28, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2022 financial results after...

1 year ago - PRNewsWire